Health Effects of Colonic Microbiota-Derived Catabolites of Flavonoids
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".
Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 12034
Special Issue Editor
Interests: anticancer actions of natural products; plant polyphenols; flavonoids
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Flavonoids constitute an important part of health-promoting constituents of various plant-derived food products, such as fruits, vegetables, nuts, medicinal plants, spices, and teas. Over recent years, significant focus has been placed on the metabolic conversion of these dietary polyphenolic agents in the small intestine and the liver, as a result of which conjugated flavonoids and not the parent aglycones enter the systemic circulation. However, a large portion of the ingested flavonoids can pass the small intestine non-absorbed and reach the colon where they will be the subject of intestinal microbiota-mediated degradation into a wide variety of smaller aromatic products, mainly phenolic acids. These colonic catabolites can then be absorbed and metabolized in the liver, before becoming bioavailable to the target tissues. Although the resulting gut microbiota-derived products are different chemical entities from their parent flavonoids, the current knowledge about their bioactivities and possible health effects is still rather scarce. For example, it is found that some colonic catabolites of flavonoids, such as protocatechuic acid, can exert neuroprotective and cardioprotective activities, while others, such as gallic acid and daidzein-derived equol, possess anticancer properties, besides acting as antioxidant and anti-inflammatory agents. To intensify the development of this important research field, the current Special Issue is focused on the structural identification of gut microbial products of flavonoids and description of their different types of bioactivities in diverse biological systems. It is highly expected that the results of these studies will lead to the determination of novel lead compounds as potential candidates for the drug discovery process.
Dr. Katrin Sak
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- flavonoids
- gut microbial products
- phenolic acids
- bioactivities
- antioxidant
- anti-inflammatory
- anticancer
- chemoprevention
